Skip to Main Content

It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in my mind, is whether she died in vain.

I’d like to think not.


During her final months, the 52-year-old former public relations executive battled Biogen, one of the world’s largest biotech companies, for access to an experimental treatment for ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.